CD1D Antibody (C-9): sc-271950
- CD1D Antibody (C-9) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- raised against amino acids 71-140 mapping near the N-terminus of CD1D of human origin
- recommended for detection of CD1D of human origin by WB, IP, IF and ELISA
- See CD1D (C3D5): sc-19632 for CD1D antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CD1D Antibody (C-9) for WB applications. These reagents are now offered in bundles with CD1D Antibody (C-9) (see ordering information below).
QUICK LINKS
CD1D Antibody (C-9) is a mouse monoclonal IgG2b antibody that detects CD1D in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD1D is a crucial member of the CD1 multigene family, which encodes five forms of the CD1 T cell surface glycoprotein, and plays a significant role in the immune system by presenting lipid antigens to T lymphocytes. CD1D is primarily located on the surface of human intestinal epithelial cells, where CD1D exists in two forms: a β-2-Microglobulin-independent nonglycosylated form and a β-2-Microglobulin-dependent glycosylated form. CD1D expression on these cells is vital for the regulation of immune responses in the gut, influencing the maturation and activation of CD1-restricted T cells. The human CD1D gene is mapped to chromosome 1q23.1 and encodes a 335 amino acid protein that is essential for maintaining normal T cell development. Anti-CD1D antibody (C-9) is an invaluable tool for researchers studying immune responses, particularly in the context of lipid antigen presentation and T cell maturation.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD1D Antibody (C-9) References:
- Antigen recognition by CD1d-restricted NKT T cell receptors. | Godfrey, DI., et al. 2010. Semin Immunol. 22: 61-7. PMID: 19945889
- Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. | Metelitsa, LS. 2011. Clin Immunol. 140: 119-29. PMID: 21095162
- CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis. | Bojarska-Junak, A., et al. 2014. Leuk Res. 38: 435-42. PMID: 24418751
- The effect of intracellular trafficking of CD1d on the formation of TCR repertoire of NKT cells. | Shin, JH. and Park, SH. 2014. BMB Rep. 47: 241-8. PMID: 24755556
- CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis. | Schneiders, FL., et al. 2014. Cancer Immunol Res. 2: 732-40. PMID: 24934445
- Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses. | Webb, TJ., et al. 2016. Pathog Dis. 74: PMID: 27297969
- CD1d-mediated lipid presentation by CD11c+ cells regulates intestinal homeostasis. | Sáez de Guinoa, J., et al. 2018. EMBO J. 37: PMID: 29378774
- CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy. | Hara, A., et al. 2021. Cancer Immunol Immunother. 70: 1239-1254. PMID: 33128583
- Adipose invariant NKT cells interact with CD1d-expressing macrophages to regulate obesity-related inflammation. | Satoh, M., et al. 2022. Immunology. 165: 414-427. PMID: 35137411
- Cancer-associated fibroblasts express CD1d and activate invariant natural killer T cells under cellular stress. | Pei, S., et al. 2024. Cell Mol Immunol. 21: 91-94. PMID: 37735500
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD1D Antibody (C-9) | sc-271950 | 200 µg/ml | $322.00 | |||
CD1D Antibody (C-9): m-IgGκ BP-HRP Bundle | sc-535070 | 200 µg Ab; 40 µg BP | $361.00 | |||
CD1D Antibody (C-9): m-IgG2b BP-HRP Bundle | sc-549339 | 200 µg Ab; 10 µg BP | $361.00 |